Anavex Life Sciences Corp. (AVXL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.86+0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVXL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 10.0 | 13.8 | — | 12.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D Expenses | — | 37.6 | 41.8 | 43.7 | 37.9 | 33.0 | 25.2 | 22.3 | 13.3 | 10.7 | 7.3 | 2.3 | 0.7 | 0.3 | 2.7 | 2.6 |
| Operating Income | (17.4) | (51.4) | (52.9) | (55.8) | (51.0) | (42.0) | (31.1) | (26.2) | (17.2) | (13.4) | (14.7) | (12.1) | (3.0) | (2.1) | (4.3) | (6.2) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 |
| Other Non-Operating Income / Expenses | 4.4 | 5.0 | 9.9 | 8.3 | 3.4 | 4.4 | 4.8 | 2.9 | 2.2 | 2.3 | 0.9 | (5.0) | (8.4) | — | — | — |
| EBT, Incl. Unusual Items | — | (46.4) | (43.0) | (47.5) | (47.6) | (37.6) | (26.3) | (26.2) | (17.2) | (13.4) | (14.7) | (12.1) | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — | — | — | — | (1.4) | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (13.0) | (46.4) | (43.0) | (47.5) | (48.0) | (37.9) | (26.3) | (26.3) | (17.3) | (13.5) | (14.7) | (12.1) | (10.0) | (3.7) | (8.3) | (7.3) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.00) | (0.54) | (0.52) | (0.60) | (0.62) | (0.54) | — | — | — | — | (0.42) | (0.65) | (1.02) | — | — | — |
| Diluted EPS | (0.00) | (0.54) | (0.52) | (0.60) | (0.62) | (0.54) | — | — | — | — | (0.42) | (0.65) | (1.02) | (0.12) | (0.29) | (0.29) |
| Basic Weighted Avg Shares | 92,696.8 | 85.3 | 83.5 | 79.8 | 76.9 | 69.8 | — | — | — | — | 35.2 | 18.6 | 9.8 | — | — | — |
| Diluted Weighted Avg Shares | 92,899.5 | 85.3 | 83.5 | 79.8 | 76.9 | 69.8 | — | — | — | — | 35.2 | 18.6 | 9.8 | 31.9 | 28.2 | 25.2 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | (17.2) | (13.4) | (14.7) | (12.1) | (3.0) | (2.1) | (4.3) | (6.2) |
| EBIT | (17.4) | (51.4) | (52.9) | (55.8) | (51.0) | (42.0) | (31.1) | (26.2) | (17.2) | (13.4) | (14.7) | (12.1) | (3.0) | (2.1) | (4.3) | (6.2) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | — | — | 11.6% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.